In conversation with IAVI founder Seth Berkley and CEO Mark Feinberg

A timeline of major milestones in the decades-long effort to develop an HIV vaccine.

John Nkengasong warns against complacency setting in as vaccines trickle into many African countries.

Researchers describe the experimental HIV vaccine approach called germline targeting as “shepherding” the immune system. They hope it will lead to greener pastures.

The last time I penned a letter in this publication, nearly a year ago, I closed by saying: “If science is our best hope, we are in good hands.” That certainly proved to be the case. There are now three authorized COVID-19 vaccines in the U.S., and seven that have received an Emergency Use Listing…

In conversation with four experts who are applying lessons from the decades-long battle against HIV/AIDS to the ongoing COVID-19 pandemic.

How will the results from recent trials set the course for future research?

SARS-CoV-2 is the first Disease X. There will certainly be others. Will the world be better prepared for the next one?

An interview with Seth Berkley, chief executive officer of Gavi, the Vaccine Alliance

Scientists are applying decades of HIV research experience to the development of SARS-CoV-2 vaccines in the race to end the pandemic.